A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

ClinicalTrials.gov ID: NCT05652335

Public ClinicalTrials.gov record NCT05652335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 9, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Study identification

NCT ID: NCT05652335
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 180 participants

Conditions and interventions

Conditions

Interventions

JNJ-79635322 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 21, 2022
Primary completion: Apr 18, 2027
Completion: Aug 27, 2028
Last update posted: May 7, 2026

2022 – 2028

United States locations

U.S. sites: 9
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
City of Hope Orange County Lennar Foundation Cancer Center	Irvine	California	92618	Recruiting
University of California San Francisco	San Francisco	California	94143	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Icahn School of Medicine at Mt. Sinai	New York	New York	10029	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28001	Recruiting
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine	Philadelphia	Pennsylvania	19104	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05652335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 7, 2026 · Synced May 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05652335 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →